Literature DB >> 2836347

Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin.

K Nakagawa1, J Yokota, M Wada, Y Sasaki, Y Fujiwara, M Sakai, M Muramatsu, T Terasaki, Y Tsunokawa, M Terada.   

Abstract

The amounts of mRNA for glutathione S transferase pi (GST pi) were significantly lower in 3 human small cell lung cancer (SCLC) cell lines than in 3 non small cell lung cancer (NSCLC) cell lines. The sensitivities of the 3 SCLC cell lines to cisplatin and carboplatin were much higher than those of the 3 NSCLC cell lines. These results indicate that low levels of GST pi mRNA expression in SCLC cell lines inversely correlate to high sensitivity to cisplatin and carboplatin, and further suggest that GST pi may play an important role in intracellular inactivation of these drugs.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2836347      PMCID： PMC5917487          DOI： 10.1111/j.1349-7006.1988.tb01590.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  13 in total

1.  Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.

Authors:  C R Wolf; I P Hayward; S S Lawrie; K Buckton; M A McIntyre; D J Adams; A D Lewis; A R Scott; J F Smyth
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

2.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

Authors:  T C Hamilton; M A Winker; K G Louie; G Batist; B C Behrens; T Tsuruo; K R Grotzinger; W M McKoy; R C Young; R F Ozols
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

3.  Chemosensitivity test for human small cell lung cancer cell lines in vitro.

Authors:  H Takahashi; N Saijo; T Shinkai; K Eguchi; Y Sasaki; T Tamura; T Sano; H Nakano; K Nakagawa; M Sakurai
Journal:  Jpn J Clin Oncol       Date:  1986-09       Impact factor: 3.019

4.  Isolation and expression of a complementary DNA that confers multidrug resistance.

Authors:  P Gros; Y B Ben Neriah; J M Croop; D E Housman
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

5.  Changes in cell characteristics due to culture conditions in cell lines from human small cell lung cancer.

Authors:  T Terasaki; Y Shimosato; T Nakajima; M Tsumuraya; S Morinaga; S Hirohashi; K Yamaguchi; K Kato; H Ichinose; T Nagatsu
Journal:  Jpn J Clin Oncol       Date:  1986-09       Impact factor: 3.019

Review 6.  Glutathione metabolism as a determinant of therapeutic efficacy: a review.

Authors:  B A Arrick; C F Nathan
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

7.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

Authors:  B A Teicher; S A Holden; M J Kelley; T C Shea; C A Cucchi; A Rosowsky; W D Henner; E Frei
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

8.  Structure and expression of a human class pi glutathione S-transferase messenger RNA.

Authors:  T Kano; M Sakai; M Muramatsu
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

9.  Cloning and the nucleotide sequence of rat glutathione S-transferase P cDNA.

Authors:  Y Suguoka; T Kano; A Okuda; M Sakai; T Kitagawa; M Muramatsu
Journal:  Nucleic Acids Res       Date:  1985-09-11       Impact factor: 16.971

10.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

Authors:  I B Roninson; J E Chin; K G Choi; P Gros; D E Housman; A Fojo; D W Shen; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205
View more
  22 in total

1.  Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors.

Authors:  Alexander J Neuwelt; Tam Nguyen; Y Jeffrey Wu; Andrew M Donson; Rajeev Vibhakar; Sujatha Venkatamaran; Vladimir Amani; Edward A Neuwelt; Louis B Rapkin; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-08-17       Impact factor: 3.167

2.  Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma.

Authors:  Ying-Jen Jeffrey Wu; Alexander J Neuwelt; Leslie L Muldoon; Edward A Neuwelt
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

Review 3.  Pharmacogenomics of cisplatin-induced ototoxicity.

Authors:  Debashree Mukherjea; Leonard P Rybak
Journal:  Pharmacogenomics       Date:  2011-07       Impact factor: 2.533

4.  In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

Authors:  Y Heike; M Takahashi; T Ohira; H Arioka; Y Funayama; K Nishio; H Ogasawara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity.

Authors:  Danyelle M Townsend; Kenneth D Tew; Lin He; Jarrod B King; Marie H Hanigan
Journal:  Biomed Pharmacother       Date:  2008-09-07       Impact factor: 6.529

6.  Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Authors:  H Parekh; H Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 7.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

8.  Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines.

Authors:  Alexander J Neuwelt; Y Jeffrey Wu; Narcyz Knap; Marcin Losin; Edward A Neuwelt; Michael A Pagel; Steven Warmann; Joerg Fuchs; Piotr Czauderna; Michal Wozniak
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

Review 9.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 10.  7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.

Authors:  N Saijo; K Nishio; N Kubota; F Kanzawa; T Shinkai; A Karato; Y Sasaki; K Eguchi; T Tamura; Y Ohe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.